Ultimovacs ASA: Ultimovacs' Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy
Data from three trials of UV1 show dynamic T cell responses, lasting up to 7.5 yearsUV1-specific immune responses associated with longer clinical survivalSynergy between UV1 vaccination and checkpoint
Source: finanznachrichten.de